Lizza Hendriks
YOU?
Author Swipe
View article: Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity Open
Purpose The combination of lazertinib and amivantamab has shown superior efficacy over first line osimertinib in EGFR-mutated metastatic non-small cell lung cancer, but is associated with significant toxicity and high costs. Lazertinib exp…
View article: Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry
Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry Open
Systemic therapies can substantially improve survival in patients with NSCLC with LM at diagnosis and should therefore no longer be considered an automatic exclusion criterion for active treatment.
View article: AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective study
AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective study Open
This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0531100, 2024ZD0531101), the National Natural Science Foundation of China (82472062, 62102103, 82473298, 82202148, 8250247…
View article: Improving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study
Improving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study Open
Background Making informed decisions about clinical trial participation can be overwhelming for patients due to the complexity of trial information, potential risks and benefits, and the emotional burden of a recent diagnosis. Patient deci…
View article: DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies
DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies Open
The Dutch Thoracic Oncology Cohort (DuTOC) is a nationwide cohort for patients with thoracic malignancies collecting patient characteristics, quality of life and biomaterials after informed consent of the patient. With this data and materi…
View article: Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand?
Adjuvant radiotherapy in the era of new peri-operative systemic treatments for surgically resected non-small-cell lung cancer: where do we stand? Open
The role of post-operative radiotherapy (PORT) in radically resected non-small-cell lung cancer (NSCLC) remains a topic of debate, particularly in pN2 disease. While phase III trials like PORT-C and LungART have demonstrated a significant …
View article: Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat
Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat Open
Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and reduce treatment associated costs. The OSIBOOST trial demonstrated that it was feasible to boost low osimertinib plasma trough levels with cobicistat. The curre…
View article: The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy
The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy Open
Lung cancer is the leading cause of cancer-related death world-wide. Although the standard of care for patients with advanced stage lung cancer has significantly improved with the advent of immunotherapy and targeted agents, the overall pr…
View article: Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib Open
ctDNA analysis tracks variant dynamics and can identify resistance mechanisms in patients with EGFRex20+ NSCLC treated with high-dose osimertinib, offering valuable new insights.
View article: Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series
Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series Open
• High exposures of osimertinib are associated with toxicity, and evidence for efficacy at low exposures is scarce: therapeutic drug monitoring can be applied to minimize toxicity while maintaining expected effectiveness. • CYP3A polymorph…
View article: Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment Open
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients…
View article: Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell lung cancer Open
No association was found between the presence of bone metastases and the total concentration of EVs, RANKL+ EVs, or plasma values of RANKL and OPG. In patients without SREs the concentration of RANKL+ EVs was significantly increased. Both …
View article: Improving Patient Engagement in Phase 2 Clinical Trials with a Trial-specific Patient Decision Aid (tPDA): A Development and Usability Study
Improving Patient Engagement in Phase 2 Clinical Trials with a Trial-specific Patient Decision Aid (tPDA): A Development and Usability Study Open
Background Making informed decisions about clinical trial participation can be overwhelming for patients due to the complexity of trial information, potential risks and benefits, and the emotional burden of a recent diagnosis. Patient deci…
View article: DINASTY in NSCLC – a multicenter retrospective study on real-world data using federated analysis
DINASTY in NSCLC – a multicenter retrospective study on real-world data using federated analysis Open
Real-world data is an important complement to randomized controlled trials and can be used to assess whether study results translate well to routine clinical practice and to groups of patients that are often excluded from clinical trials. …
View article: Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab Open
ICB retreatment at disease progression after CRT and durvalumab might offer an OS benefit over CT in patients who do not relapse during durvalumab treatment.
View article: Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review
Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review Open
Background Brain metastases (BM) frequently occur in patients with non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGA). Targeted therapies (TTs) improve outcomes, but differences in BM screening and eligibility cri…